key: cord-0937847-axua38yw authors: Cuykx, Matthias; Mortelé, Olivier; Jansens, Hilde; Schouwers, Sofie; Meskal, Anissa; Hoffbauer, Ilse; Peeters, Bart title: Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays date: 2021-07-10 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2021.115486 sha: a935ad783b79317c6e1c397b2b7cc94f3e216043 doc_id: 937847 cord_uid: axua38yw Spike (S)- and nucleocapsid (N)-specific serological assay responses were determined before/after first dose SARS-CoV-2 vaccination in 22 individuals. S-specific assays quantified antibodies after vaccination with significant higher levels in participants with a previous infection. Be cautious combining N-/S-specific assay results, potentially differentiating post-infection/vaccination immunization as assay-specific N-antibody waning was observed. Elecsys Anti-SARS-CoV-2: Roche anti-N tAb SARS-CoV-2 IgG assay: Abbott anti-N IgG Currently two severe acute respiratory syndrome coronavirus 2 vaccine forms have been approved by the European Medicines Agency involving messenger RNA (mRNA) (mRNA-1273, Moderna; BNT162b2, Pfizer) or a nonreplicating viral vector (AZD1222, AstraZeneca; Ad26 Cov S1, Janssen Pharmaceutical). Efficacy at preventing severe infections and hospitalization was close to 100% in phase 3 trials of these vaccines after administration of two doses. These trials included mainly participants without previous SARS-CoV-2 infection [1, 2] . After a first wave of automated qualitative serological assays targeting spike (S-) or nucleocapsid (N-) antibodies, most manufacturers launched quantitative tests targeting S-antibodies, considering that all current vaccines trigger anti-SARS-CoV-2 S-antigen antibody formation [1] [2] [3] . Manufacturers evaluated clinical sensitivity using samples from subjects immunized through natural SARS-CoV-2 infection but not through vaccination. None of the manufacturers gives any information regarding the performance or capability to detect antibodies of the assay after vaccination. The first studies are emerging, shedding light on the antibody response after a single dose of SARS-CoV-2 vaccine [4, 5] . By definition, vaccination-induced immunization for Using the Roche anti-N tAb assay, the 'anti-S positive' and 'anti-N negative' serological response was seen in 11 samples from individuals without a prior infection; 10 were pre-booster samples (all S-specific assays were positive) and one was a baseline sample with a positive Liaison anti-TriS result (all other S-specific SARS-CoV-2 antibody assays after vaccination 6 assays were negative). Using the Abbott anti-N IgG assay, this serological response was seen in 27 samples consisting of the same 11 samples as described for the Roche assay and 16 additional samples (eight baseline and eight pre-booster) from eight participants with a previous infection with the 'anti-S positive' and 'anti-N negative' serological response. The anti-N IgG antibodies measured by the Abbott assay were reported to have a half-life of 106 days making this assay prone to antibody waning [6] . This waning phenomenon is not seen in the Roche anti-N tAb assay [7] . In our study, baseline sampling was performed a median 209 days (2 times the antibody half-life) after SARS-CoV-2 infection. All 12 individuals with a previous infection had a positive Roche N-antibody response of which eight had a negative Abbott N-antibody response. The S-specific assays from Roche, Siemens, DiaSorin and Abbott detected and quantified anti-S antibodies pre-booster and/or infection; however, protective levels are not provided for any of these assays. Significantly higher pre-booster antibody levels were observed in persons with a previous SARS-CoV-2 infection for all Sspecific assays. Despite the small sample size and low statistical power, conclusions were statistically significant using non-parametric statistics. The findings of this study should be checked in larger population-based studies, increasing the statistical power, although we believe that similar conclusions will be drawn. Clinicians should be aware of the phenomenon of assay-specific antibody waning when using the combination of N-and S-specific serological assays to differentiate individuals with post-infection or vaccination immunization and should use an Nspecific assay with a robust antibody response (e.g. Roche anti-N tAb assay). One should also be aware of possible false positive results from S-specific assays and inter-individual differences in antibody responses after SARS-CoV-2 infection as 3-SARS-CoV-2 antibody assays after vaccination 7 4% of individuals with a previous infection seemed to be serological non-responders in a large population-based study by Baron et al. [8] . As previous infection is not a contraindication for vaccination and guidelines for apparent 'non-responders' are lacking, we conclude that serologic testing prior or post-vaccination is not standard clinical practice yet. Nonetheless, performant quantitative serological assays will play an important role in research to establish protective antibody levels. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates SARS-CoV-2 antibody assays after vaccination 8 SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study Matthias Cuykx: Conceptualization; Data curation; Formal analysis; Investigation Validation; Visualization; Revising the article; Final approval of the version to be submitted Acquisition of data Acquisition of data Acquisition of data Acquisition of data Acquisition of data Bart Peeters: Conceptualization; Data curation; Formal analysis Investigation; Methodology Supervision; Validation; Visualization Roles/Writing -original draft; Writing -review & editing SARS-CoV-2 antibody assays after vaccination 10 Figure 1: Log-scaled baseline and pre-booster antibody levels for SARS-CoV-2 Full horizontal lines display the median baseline/pre-booster antibody levels in individuals without (Abbott anti-S IgG: <3.00/67 BAU/mL; Liaison anti-TriS IgG: <4.8/198 BAU/mL; Roche anti-S tAb: <0.40/49 BAU/mL and Siemens anti-S IgG: <10.9/87 BAU/mL) and with (Abbott anti-S IgG: 57/3215 BAU/mL; Liaison anti-TriS IgG: 86/6786 BAU/mL 178/18090 BAU/mL and Siemens anti-S IgG: 65/5167 BAU/mL) a previous SARS-CoV-2 infection